Gu Hai Ou, aged 59, is an executive director and the chairman of the board of directors of the Company. Mr. Gu is currently the vice general manager and member of Standing Committee of Party Committee of China Beijing Tong Ren Tang Group Co., Ltd., and the vice president of the China Association of Traditional Chinese Medicine. Mr. Gu was an executive director and the chairman of board of directors of Tong Ren Tang Technologies Co. Ltd. (a company listed on The Stock Exchange of Hong Kong Limited, (stock code: 1666), and a controlling shareholder of the Company), and resigned on 22 January 2024. Mr. Gu joined Beijing Tong Ren Tang Group in 1991 and was formerly the vice general manager, the chief engineer, director, the chairman of board of directors of Beijing Tong Ren Tang Company Limited. Mr. Gu graduated from the Shanghai University of Traditional Chinese Medicine in July 1986 with a bachelor’s degree, and obtained a master’s degree in medical science from Beijing University of Chinese Medicine in July 1991. Mr. Gu holds the title of researcher and is also a licensed pharmacist.

Wang Chi, aged 49, is an executive director and the chief executive officer of the Company. Mr. Wang has more than 20 years of experience in medical and pharmaceutical industry. Mr. Wang joined Beijing Tong Ren Tang Pharmaceutical Company Limited* (北京同仁堂制药有限公司) (“Pharmaceutical Company”), a subsidiary of China Beijing Tong Ren Tang Group Co., Ltd., and served as a director and the general manager of Pharmaceutical Company. Prior to joining Beijing Tong Ren Tang Group, Mr. Wang was the general manager of the Jiangzhong Food Therapy Company Limited and chairman and general manager of subsidiaries and various senior positions in Humanwell Healthcare (Group) Co., Ltd. (a company is listed on the Shanghai Stock Exchange, stock code: 600079). Mr. Wang attained a bachelor's degree in Mechanical Manufacture and Design from Department of Mechanical Engineering of Wuhan University (formerly known as Wuhan University of Hydraulic and Electric Engineering) in 1996, and obtained a master’s degree in Business Administration from Economics and Management School of Wuhan University in 2003, and then obtained a Ph.D. in Management from Economics and Management School of Wuhan University in 2011.

*For identification purposes only

Chen Fei, aged 54, is an executive director and the executive deputy general manager of the Company, and a director of various subsidiaries of the Company. Mr. Chen was appointed as a non-executive director of the Company on 24 March 2020 and was re-designated as an executive director and was appointed as the chief executive officer of the Company on 11 March 2021. He was re-designated as the executive deputy general manager of the Company on 19 April 2023. Mr. Chen served as the acting chief executive officer of the Company from 28 March 2024 to 10 May 2024. Mr. Chen joined Beijing Tong Ren Tang Group in August 1994 and formerly served as the manager and the deputy manager of Operational Management Department of Tong Ren Tang Holdings, the deputy manager of Pricing Department of Tong Ren Tang Holdings, the deputy manager of Economic Operation Department of Tong Ren Tang Holdings and the general manager of Beijing Tong Ren Tang (Thailand) Co., Ltd.. Mr. Chen obtained a bachelor’s degree in Chinese medicine from School of Chinese Medicine of Beijing Union University in August 1994.

Feng Li, aged 49, is a non-executive director of the Company, who was appointed as an executive director of the Company on 12 August 2022 and re-designated as a non-executive director on 13 March 2023. Ms. Feng currently serves as a non-executive director of Tong Ren Tang Technologies Co. Ltd. (a company listed on The Stock Exchange of Hong Kong Limited, stock code: 1666), a controlling shareholder of the Company and the deputy general manager and the secretary to the board of directors of Beijing Tong Ren Tang Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600085), a controlling shareholder of the Company. Ms. Feng joined Beijing Tong Ren Tang Group in March 2012 and was formerly served as the manager of the Internal Audit and Legal Department, the assistant to the general manager and the manager of the Economic Operation Department of the Company. Prior to joining Beijing Tong Ren Tang Group, Ms. Feng worked as a senior audit manager at PricewaterhouseCoopers Zhongtian LLP. Ms. Feng graduated from the Department of International Economics of Peking University in 1998 with a bachelor's degree in economics and she is also a certified public accountant in China (non-practicing).

 

Tsang Yok Sing, Jasper, G.B.M., G.B.S., J.P., aged 77, was appointed as an independent non-executive director of the Company on 12 September 2017. Mr. Tsang is an Honorary Professor of the Faculty of Social Science of The Chinese University of Hong Kong. Mr. Tsang currently serves as an independent non-executive director of Kunlun Energy Company Limited (stock code: 135) which is listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). Mr. Tsang held a number of posts in public service, including the President of the Fourth and the Fifth Legislative Council of the HKSAR from 2008 to 2016. Prior to his election as President of the Legislative Council of the HKSAR, Mr. Tsang served as a member of the Legislative Council from 1998 to 2016, representing the Kowloon West constituency from 1998 to 2008 and the Hong Kong Island constituency from 2008 to 2016. He served as a member of the Executive Council of the HKSAR from 2002 to 2008. From 1992 to 2003, he served as chairman of the Democratic Alliance for the Betterment of Hong Kong. Mr. Tsang was actively involved in the establishment of the HKSAR. He served as a member of the Preparatory the Committee established by the Standing Committee of the Chinese National People’s Congress in 1996 and a member of the Provisional Legislative Council of the HKSAR from 1997 to 1998. Mr. Tsang was a member of the National Committee of the Chinese People’s Political Consultative Conference from 1993 to 2013, a non-executive director of the Hong Kong Securities and Futures Commission from 2001 to 2007, a member of the Executive Committee of the Commission on Strategic Development from 2005 to 2008, a board member of the Airport Authority Hong Kong from 2005 to 2008, a member of the Independent Commission Against Corruption Complaints Committee from 2003 to 2008 and a member of the Disaster Relief Fund Advisory Committee from 2002 to 2008. Mr. Tsang also served as a member of the Council of The Open University of Hong Kong from 1996 to 2005 and a member of the Standing Committee on Language Education and Research from 1996 to 2000. Mr. Tsang obtained a Bachelor of Arts degree at The University of Hong Kong in 1968, Certificate in Education at the University of Hong Kong in 1981 and a Master of Education degree at the University of Hong Kong in 1983. Mr. Tsang was appointed as a Justice of the Peace (J.P.) in 1998 and was awarded the Gold Bauhinia Star (G.B.S.) in 2002 and the Grand Bauhinia Medal (G.B.M.) in 2015. Mr. Tsang previously served as an independent non-executive director of DTXS Silk Road Investment Holdings Company Limited (stock code: 620) which is listed on the Stock Exchange, his tenure of office expired on 31 August 2023.

Xu Hong Xi, aged 63, was appointed as an independent non-executive director of the Company on 13 March 2023. Mr. Xu is currently the chief professor of Shanghai University of Traditional Chinese Medicine, the honorary dean of the School of Pharmacy and the head of Shanghai College Engineering Research Center for Innovative Pharmaceutical Research and Development of Chinese Medicine. Mr. Xu serves as a distinguished professor of Organization Department of the Central Committee of the Chinese Communist Party, the first batch “Shanghai Distinguished Expert” and concurrently serves as the secretary-general of Chinese Medicine Academic Disciplinary Assessment team of the State Council Academic Degrees Committee, a member of Chinese Medicine Professional Education Steering Committee under Ministry of Education, a member of Chinese Pharmacopoeia Commission, the chairman of Chinese Medicine Experimental Pharmacology Branch of China Association of Chinese Medicine, the chairman of Chinese Medicine Professional Committee of Shanghai Pharmaceutical Association, the co-chairman of International Conference of the Modernization of Chinese Medicine. Mr. Xu successively served as the scientific officer of Chinese Medicine Research Centre at The Chinese University of Hong Kong, the deputy general manager and senior medical advisor of Hutchison Whampoa (China) Limited, a director and the R & D director of Shanghai Hutchison Pharmaceuticals Limited, and the deputy director of Hong Kong Jockey Club Institute of Chinese Medicine. Mr. Xu graduated from Shanghai University of Traditional Chinese Medicine in 1983 and 1989 with a bachelor’s degree and master’s degree, respectively, and obtained his Ph.D. degree in Pharmaceutical Sciences in 1994 from Toyama Medical and Pharmaceutical University in Japan, and conducted postdoctoral research in National University of Singapore and Dalhousie University in Canada between 1994 and 1998.

Chan Ngai Chi, aged 52, was appointed as an independent non-executive director of the Company on 15 April 2013. Prior to joining the Company, Mr. Chan had more than 20 years of financial management, compliance and auditing experience. Mr. Chan worked in the audit division of PricewaterhouseCoopers Hong Kong and various Hong Kong and U.S. listed companies. Mr. Chan is currently the chief financial officer and company secretary of International Business Digital Technology Limited (formerly known as Vixtel Technologies Holdings Limited) (stock code: 1782), which is listed on The Stock Exchange of Hong Kong Limited. Mr. Chan is a fellow member of the Hong Kong Institute of Certified Public Accountants and the Association of Chartered Certified Accountants, and also a Chartered Financial Analyst Charterholder. Mr. Chan graduated from the Hong Kong University of Science and Technology with a bachelor’s degree in business administration in accounting in 1994 and, also obtained a master’s degree in Science from the Chinese University of Hong Kong in 2003 and an EMBA degree from Peking University in 2021.